In the long arc of biotechnology's promise, a small Taiwanese firm named Obigen Pharma has moved its most consequential clinical milestone two months closer, signaling that its long-acting botulinum toxin candidate may reach patients sooner than the market anticipated. On September 8, chief executive Chou Pei-fen told investors that Phase 3 trial data could be unblinded as early as November, opening the path to a Taiwan regulatory filing in early 2027 and a commercial launch in 2028. Behind the timeline lies a year of careful safety study — 200 subjects, hundreds of treatment sessions, and a d